Navigation Links
Clarus Ventures Names Two New Partners
Date:1/5/2009

Dr. Emmett Cunningham and Scott Requadt Promoted From Principals

CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., Jan. 5 /PRNewswire/ -- Clarus Ventures, LLC ("Clarus Ventures"), a leading life sciences venture capital firm, announced today the promotions of Emmett Cunningham, M.D., Ph.D., M.P.H., to Partner and Scott Requadt, J.D., M.B.A., to Transactional Partner, effective Jan. 1, 2009.

Dr. Cunningham joined Clarus in 2006 and represents the firm as a Director on the Board of SARcode and as a Board Observer at FerroKin, Pearl, Taligen and Zogenix. He is also a member of the Scientific Advisory Boards of ESBATech and CoMentis. Dr. Cunningham joined Clarus from Eyetech Pharmaceuticals, where he was Senior Vice President of Medical Strategy and helped build and lead the development and commercialization of Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, where he was responsible for the clinical development of early-phase CNS compounds and the in-licensing of early- and late-stage therapeutic candidates in ophthalmology.

In addition to his extensive clinical, scientific and operating experience in the pharmaceutical, biotech and medtech industries, Dr. Cunningham is an internationally recognized specialist in eye diseases with more than 200 publications. In addition to his investing responsibilities at Clarus, he is an Adjunct Clinical Professor of Ophthalmology at Stanford. Dr. Cunningham received his M.D. and M.P.H. degrees from Johns Hopkins University and his Ph.D. degree in neuroscience from the University of California at San Diego. He completed his residency in ophthalmology and his fellowship training in corneal disease and uveitis at the University of California, San Francisco.

"Emmett has demonstrated a superior understanding of a wide array of therapeutic areas and has been instrumental in helping select Clarus portfolio companies and advance their business plans," said Robert Liptak, a Managing Director at Clarus.

Scott Requadt joined Clarus in 2005 and represents the firm as a Director on the Board of TyRx Pharma and as a Board Observer at Biolex, Oxford Immunotec, Link Medicine and Variation. He joined Clarus from TransForm Pharmaceuticals shortly after the company's sale to Johnson & Johnson. While at TransForm and as Director of Business Development, Requadt was responsible for corporate development, business development and legal activities, including managing the intellectual property group. Prior to TransForm, Requadt was an attorney specializing in mergers & acquisitions at the New York City-based law firm of Davis Polk & Wardwell, where he completed numerous public and private deals worth in excess of $1 billion, negotiated credit facilities of more than $10 billion and represented two companies during their initial public offerings. Before this, Requadt was a law clerk for a senior judge at the Supreme Court of Canada. Requadt holds a B.Com (Economics & Finance) from McGill University, a J.D. from the University of Toronto and an M.B.A. from Harvard Business School, where he was a Baker Scholar.

"In addition to his contributions in identifying and evaluating new investment opportunities, Scott's legal and business background will enable him to play a unique and crucial role across Clarus portfolio companies during investment, partnering and transaction endeavors," said Liptak.

About Clarus Ventures

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds that have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus is based in Cambridge, Mass., and South San Francisco, Calif., and presently manages more than $1.2 billion across two life-sciences dedicated funds.

For additional information on Clarus Ventures, please visit www.clarusventures.com.

    CONTACTS:
    Robert Liptak, Clarus Ventures, Tel.: 617-949-2222
    Tony Russo, Russo Partners, Tel.: 212-845-4251


'/>"/>
SOURCE Clarus Ventures, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clarus Ventures Closes $660 Million Fund
2. Hank Plain Joins Morgenthaler Ventures as Partner
3. Dan Broderick Joins Prolog Ventures as Partner
4. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
5. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
6. Khosla Ventures and BIOeCON Form KiOR Inc.
7. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
8. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):